Format

Send to

Choose Destination
Expert Rev Vaccines. 2005 Aug;4(4):493-502.

MUC1 as a target antigen for cancer immunotherapy.

Author information

1
Department of Medical and Regulatory Affairs, Transgene, 67082 Strasbourg, France. acres@transgene.fr

Abstract

The cancer-associated antigen MUC1 is overexpressed and modified by tumor cells in over half of all cancer cases. Despite various complexities associated with this antigen, it is well worth pursuing as a vaccine for the immunotherapy of cancer. In this review, the authors describe the discovery of MUC1 and its association with cancer, recent observations showing that the immunology of MUC1 is complicated, animal data showing that it can be a target for immune-mediated tumor rejection, and finally, preliminary clinical results to show that vaccine-based immunotherapy with MUC1 does have an impact on the therapy of cancer.

PMID:
16117706
DOI:
10.1586/14760584.4.4.493
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center